Evidence map›Paper›PMID 25595778›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

ShcA regulates late stages of T cell development and peripheral CD4+ T cell numbers.

Monica W Buckley, Paul C Trampont, Sanja Arandjelovic, Aaron M Fond, Ignacio J Juncadella, Kodi S Ravichandran

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Monica W BuckleyDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908.
Paul C TrampontDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908.
Sanja ArandjelovicDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908.
Aaron M FondDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908.
Ignacio J JuncadellaDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908.
Kodi S RavichandranDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908; Carter Immunology Center, University of Virginia, Charlottesville, VA 22908; and Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908 Ravi@virginia.edu.
Carter Center · USUniversity of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Role of ELMO and DOCK 180 in signaling to engulfmentR01GM064709 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LORENZ, ULRIKE, RAVICHANDRAN, KODI S · 2003 to 2016
$3.6M
SIGNALING VIA SHC AND THE INOSITOL PHOSPHATASE, SHIPR01GM055761 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI RAVICHANDRAN, KODI S · 1998 to 2011
$3.2M
Role of Shcbp1 (mPAL) in T Cell Development and FunctionF30CA177173 · NCI · UNIVERSITY OF VIRGINIA · PI BUCKLEY, MONICA WEAVER · 2013 to 2015
$108k
NCI NIH HHS F30 CA177173NCI NIH HHS P30 CA044579NIAID NIH HHS T32 AI007496NIGMS NIH HHS GM55761NIGMS NIH HHS R01 GM055761NIGMS NIH HHS R01 GM064709NIGMS NIH HHS T32 GM007267
6 · The paper itself

Abstract

T cell development in the thymus is a highly regulated process that critically depends upon productive signaling via the preTCR at the β-selection stage, as well as via the TCR for selection from the CD4(+)CD8(+) double-positive stage to the CD4 or CD8 single-positive stage. ShcA is an adapter protein expressed in thymocytes, and it is required for productive signaling through the preTCR, with impaired signaling via ShcA leading to a developmental block at the β-selection checkpoint. However, the role of ShcA in subsequent stages of T cell development has not been addressed. In this study, we generated transgenic mice (CD4-Cre/ShcFFF mice) that specifically express a phosphorylation-defective dominant-negative ShcA mutant (ShcFFF) in late T cell development. Thymocytes in CD4-Cre/ShcFFF mice progressed normally through the β-selection checkpoint, but displayed a significant reduction in the numbers of single-positive CD4(+) and CD8(+) thymocytes. Furthermore, CD4-Cre/ShcFFF mice, when bred with transgenic TCR mouse strains, had impaired signaling through the transgenic TCRs. Consistent with defective progression to the single-positive stage, CD4-Cre/ShcFFF mice also had significant peripheral lymphopenia. Moreover, these CD4-Cre/ShcFFF mice develop attenuated disease in CD4(+) T cell-dependent experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Collectively, these data identify an important role for the adapter protein ShcA in later stages of thymic T cell development and in peripheral T cell-dependent events.

Indexed as

AnimalsCD4-Positive T-LymphocytesCell DifferentiationCell ProliferationEncephalomyelitis, Autoimmune, ExperimentalFlow CytometryFluorescent Antibody TechniqueImmunohistochemistryLymphocyte ActivationMiceMice, Inbred C57BLMice, TransgenicPrecursor Cells, T-LymphoidReverse Transcriptase Polymerase Chain ReactionShc Signaling Adaptor ProteinsSrc Homology 2 Domain-Containing, Transforming Protein 1Shc1 protein, mouseShc Signaling Adaptor ProteinsSrc Homology 2 Domain-Containing, Transforming Protein 1

Identifiers

PMID25595778
PMCPMC4381912
OpenAlexW1564533101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.